on NICOX (EPA:COX)
Nicox Reports Full Year 2024 Financials
Nicox SA announced its financial results for 2024 with revenues reaching €7.9 million, a rise from €6.9 million in 2023. This increase includes €3.0 million from the Japanese rights sale of NCX 470 to Kowa, alongside €3.0 million in VYZULTA royalties received until June 2024.
Taking an exceptional income of €13.7 million due to the transfer of future VYZULTA revenues to Soleus Capital into account, Nicox recorded a net loss of €22.4 million. The impairment of an intercompany receivable related to ZERVIATE significantly influenced this outcome.
Cash reserves at the end of 2024 stood at €10.5 million. Operating expenses were reduced to €18.7 million from €24.2 million in 2023. While the company's financial debt amounted to €15.1 million, it remains financed through Q4 2025.
Nicox plans to update stakeholders on two NCX 470 clinical trials in 2025 while continuing partnership discussions in the U.S.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NICOX news